NEW YORK (GenomeWeb) – With a series of recent collaborations, German biomarker firm Protagen is shifting its focus to cancer immunotherapy.

Over the last year the company has signed agreements with the German National Center for Tumor Diseases, the National Cancer Institute, and the Gustave Roussy Institute of Oncology for biomarker work in immunoncology, with a specific focus on identifying patients at risk of immune-related adverse events (irAEs).

"This is the major focus of the company and has been for the last 16 months," said Georg Lautscham, Protagen's CBO.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.